Eli Lilly to trial use of weight loss drugs to combat unemployment in U.K.

Eli Lilly, a pharmaceutical company, is investing £279 million in the UK to tackle health challenges, including obesity. They will conduct a study to understand the impact of their weight-loss drug on weight loss, diabetes prevention, and employment status. The UK government views this partnership as crucial for building a healthier society and economy. However, some medical professionals are concerned about linking health treatments to economic outcomes. Eli Lilly’s investment will also support early-stage life sciences businesses in developing transformative medicines and technologies. They plan to make additional investments in the UK in the future.